A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the relative bioavailability of Flavoxate
Hydrochloride tablets 100mg manufactured by Paddock Laboratories, Inc., with that of Urispas®
tablets 100mg by SmithKline Beecham Pharmaceuticals under fasting conditions.